Ignite Creation Date:
2024-05-05 @ 11:58 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00194025
Status:
COMPLETED
Last Update Posted:
2015-01-06
First Post:
2005-09-13
Brief Title:
Valproate in Late Life Schizophrenia
Sponsor:
University Hospitals Cleveland Medical Center
Organization:
University Hospitals Cleveland Medical Center
Study Overview
Official Title:
Add-on Valproate in Late Life Schizophrenia
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to analyze the effectiveness and tolerability of a medication valproate Depakote and Depakote ER in individuals age 50 years and older who have schizophrenia
Detailed Description:
It is known that up to 30 of individuals with schizophrenia continue to have symptoms even when treated with current FDA-approved medications intended to treat their schizophrenia Anticonvulsant medications such as valproate Depakote and Depakote ER are known to be effective for related conditions such as bipolar disorder manic depressive illness and are also used by some physicians in clinical settings in combination with antipsychotic medications to treat symptoms of schizophrenia Currently Depakote and Depakote ER are approved by the FDA to treat bipolar disorder and to treat seizure disorder This study will test to see if Depakote and Depakote ER may improve symptoms of schizophrenia as well when added to antipsychotic medications
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None